|
Post by mnholdem on May 29, 2017 20:48:41 GMT -5
The company that manufacturers the Afrezza filling and assembly lines - Harro Hofliger - is located in Germany. I recall Matt stating a few years ago that it takes approximately 6-9 months to build and install, followed by testing and certifying the equipment. It would make more sense to order new equipment and ship it to a facility in China than for MannKind/Amphastar to disasemble, ship and re-assemble an existing fill line. Matt also stated the newer models are much faster than the originals, which is another reason to order new equipment and because of the potential sales volume potential for Afrezza in China, I doubt that one fill line would be able to keep up with demand anyway. Resource: www.hoefliger.com/en/applications/inhaling-insulin-instead-of-injecting/
|
|
|
Post by lakers on May 29, 2017 20:55:54 GMT -5
The company that manufacturers the Afrezza filling and assembly lines - Harro Hofliger - is located in Germany. I recall Matt stating a few years ago that it takes approximately 6-9 months to build and install, followed by testing and certifying the equipment. It would make more sense to order new equipment and ship it to a facility in China than for MannKind/Amphastar to disasemble, ship and re-assemble an existing fill line. Matt also stated the newer models are much faster than the originals, which is another reason to order new equipment and because of the potential sales volume potential for Afrezza in China, I doubt that one fill line would be able to keep up with demand anyway. Resource: www.hoefliger.com/en/applications/inhaling-insulin-instead-of-injecting/I agree with your assessment. Besides, Danbury needs to provide for ME, new North/South America countries.
|
|
|
Post by casualinvestor on May 30, 2017 9:33:39 GMT -5
Why is everybody convinced that the unidentified Middle Eastern country is the UAE given that the company has not even hinted at that? Given the history of the company, wouldn't Israel be a more likely candidate than UAE? Needle aversion, 20% diabetic population, apparently committed to combating diabetes, national health care and deep pockets. But the country doesn't matter. Any country that adds Afrezza as part of their standard of care and has national health care would be a huge win.
|
|
|
Post by lakon on May 31, 2017 6:21:37 GMT -5
Why is everybody convinced that the unidentified Middle Eastern country is the UAE given that the company has not even hinted at that? Given the history of the company, wouldn't Israel be a more likely candidate than UAE? Israel is a likely candidate, and there is the TASE listing after all. On the other hand, someone else pointed out the interest in Exubera that the UAE demonstrated years ago. Then, there is the connection to One Drop. Officials from the UAE have made public statements about addressing unmet medical needs and improving outcomes with respect to PWD. The UAE have the funds, national healthcare for top down care, large and growing incidence of PWD, and the incentive to change the standard of care without necessarily changing bad behaviors. Finally, there is the religious aspect that will likely drive the transition to Afrezza in the region as soon as they realize the medical benefits are a win-win. The UAE wants to become a center for innovation and medical tourism for Muslim nations so trying something different, like Afrezza, could fit the official agenda quite nicely. I also think that Bahrain, Qatar, Kuwait, Jordan, and Saudi Arabia will follow suit quickly after successful outcomes in the UAE spread word of mouth. Frankly, Afrezza is needed even more in Pakistan, Egypt, and Iran, but unfortunately, those markets are likely to be very challenging. www.who.int/diabetes/facts/world_figures/en/index2.html
|
|
|
Post by mnholdem on May 31, 2017 8:15:57 GMT -5
You make a very good point. Other countries in the region will take note if Afrezza becomes popular in ANY middle eastern country. The question for me is whether the plan is to deal directly with a centralized government agency of a particular country or to make a deal with a pharma or similar entity that is already set up to distribute throughout the entire region.
|
|
|
Post by brotherm1 on May 31, 2017 19:30:18 GMT -5
I think it's going to be Brazil. Population 208 million and national health care 😎
|
|
|
Post by sportsrancho on May 31, 2017 19:33:18 GMT -5
I think it's going to be Brazil. Population 208 million and national health care 😎 Love it! Cheers:-))
|
|
|
Post by mnholdem on May 31, 2017 19:40:00 GMT -5
Wow! What a prediction! Hindsight is 20/20 after all...;-)
|
|
|
Post by lakers on Jun 1, 2017 1:02:36 GMT -5
Another hint is perusing the next 2 countries Pfizer shipped Exubera or got approval for after the U.S. Just check the date. They are public info. From a 2006 PR: Exubera is the first insulin, and first ever biotechnology-based medicine to treat a systemic disorder, that can be administered without an injection. It is the only inhaled insulin to be approved for use in clinical practice in the European Union, U.S. , Brazil and Mexico, and it is pending approval in several other countries...Exubera is currently available in the U.S., United Kingdom, Ireland and Germany.ir.nektar.com/releasedetail.cfm?releaseid=210848Mnkd follows the same playbook as Pfizer in ex-US expansion, the South America Brazil.
|
|